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Background: At the time of the study, the HIV-treatment policy in South Africa included highly active antiretroviral
therapy (HAART) regimens 1 (nucleotide reverse transcriptase inhibitors (NRTIs) only), and 2 (protease inhibitors (PI)
and NRTIs). HAART is associated with the lipodystrophy syndrome, insulin resistance and reduced total adiponectin
(TA) levels. The high molecular weight (HMW):TA ratio is a superior marker of insulin resistance. The aim of this
study was to establish whether HMW:TA ratios are low in patients on PIs and whether they correlate with insulin
resistance.
Methods: This was a cross-sectional study undertaken in an antiretroviral clinic at a tertiary hospital. The participants
were 66 HIV-infected females: 22 were on regimen 2 (PI group), 22 on regimen 1 (non-PI) and 22 treatment naïve
(TN), matched for BMI and age. Patients with a history of diabetes or impaired glucose tolerance were excluded.
Serum adiponectin multimers were analysed using the AlpcoTM Adiponectin (Multimeric) enzyme immunoassay.
Waist hip ratios (WHR), glucose and insulin levels were assessed, and HOMA-IR and QUICKI calculated. Data were
analysed non-parametrically and multivariate analysis was performed.
Results: TA and HMW levels were lower in the treatment groups than in the TN group. HMW:TA was lower in the
PI than in the non-PI and TN groups, and in the non-PI than in the TN groups. HMW:TA correlated negatively with
waist, insulin and HOMA-IR, independently of BMI and duration of therapy. HOMA-IR and QUICKI did not differ
among the groups.
Conclusion: HMW:TA is significantly decreased with HAART (particularly with PIs, but also with non-PIs) and may be
a more sensitive marker of insulin resistance in these patients than conventional markers or HMW and total
adiponectin individually.
Keywords: HMW adiponectin, Lipodystrophy syndrome, HMW: adiponectin ratio, Protease inhibitors, Insulin
resistanceBackground
Adiponectin is an insulin-sensitising hormone found in
multimeric forms in the circulation with the high molecu-
lar weight (HMW) 16-18mer (>400 kDa) being the pre-
dominant and active form [1].
Although an adipokine, unlike other hormones secreted
by adipocytes, adiponectin levels are reduced in people
with increased central body fat [1], insulin resistance, type* Correspondence: fierdoz.omar@nhls.ac.za
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unless otherwise stated.2 diabetes mellitus and atherosclerosis, as well as in indi-
viduals with lipoatrophy and lipohypertrophy [1]. HMW
adiponectin has been shown to correlate better with
insulin sensitivity than total adiponectin (TA) [2] and the
HMW:TA ratio to be a better predictor of coronary artery
disease than TA [3]. The ratio has also been shown to be
suppressed in type 2 diabetes mellitus patients with coron-
ary artery disease even when HMW and TA levels were
unchanged [4].
In HIV-associated lipodystrophy, a syndrome consisting
of fat redistribution, dyslipidaemia and insulin resistance,
adiponectin levels are significantly lower, demonstrating ahis is an Open Access article distributed under the terms of the Creative
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insulin resistance [5,6]. This syndrome is associated with
antiretroviral (ARV) therapy, particularly protease inhibi-
tors (PIs) (but also nucleotide- and nucleoside reverse tran-
scriptase inhibitors such as stavudine (d4T), zidovudine
(AZT)) and didanosine (ddI) [7,8]. In such patients, thia-
zolidinedione administration, via peroxisome proliferator-
activated receptor γ activation, leads to improved insulin
sensitivity [9] with upregulation of adiponectin levels,
specifically the HMW form [10,11]. Adiponectin adminis-
tration in mice markedly ameliorates protease-induced
dyslipidaemia, suggesting that hypoadiponectinaemia may
be partially responsible for the metabolic derangements
associated with PIs [12].
In South Africa, the National Department of Health
had two highly active antiretroviral therapy (HAART) regi-
mens at the time of this study. The first regimen consisted
of d4T, lamivudine (3TC) and either efavirenz (EFV) or
nevirapine i.e. a combination of two nucleotide reverse
transcriptase inhibitors (NRTIs) and one non-nucleotide
reverse transcriptase inhibitor (NNRTIs); while the second
regimen consisted of AZT and lopinavir/ritonavir (LPV/r).
AZT and ddI are nucleotide- and nucleoside reverse
transcriptase inhibitors, respectively, while LPV/r is a PI.
The purpose of this study was to establish whether PI
therapy was associated with lower HMW:TA ratios in
HIV-infected patients, and to examine associated biochem-
ical evidence of insulin resistance in these patients.
Methods
This cross-sectional study was performed in accordance
with the Helsinki Declaration. The protocol was approved
by the University of Cape Town Faculty of Health Sciences
Research Ethics Committee with reference number REC
450/2006. Sixty-six HIV-infected African females were en-
rolled into the study into three groups, viz. PI (Regimen 2
for at least six months), non-PI (Regimen 1 for at least six
months) and treatment naïve (TN) groups, each consist-
ing of 22 patients. Subjects were recruited from the ARV
clinic at Groote Schuur Hospital, with the non-PI and TN
groups matched to the PI group for body mass index
(BMI) and age. Exclusion criteria included a history of
impaired glucose tolerance or diabetes mellitus, active
acute opportunistic infections, renal failure and preg-
nancy. Written informed consent was obtained. Waist
and hip circumferences, weight and height were mea-
sured, and the BMI and waist: hip ratio (WHR) calcu-
lated. A 75 g OGTT was performed and blood samples
drawn at 0 and 120 min. Glucose was measured at both
time points and insulin and multimeric adiponectin in the
0 min sample only. Samples were centrifuged and stored
at −70°C until analysis. The homeostatic model assess-
ment for insulin resistance (HOMA-IR) and quantitative
insulin-sensitivity check index (QUICKI) were calculated.Adiponectin was analysed using the Alpco™ Adiponectin
(Multimeric) enzyme immunoassay (sensitivity 0.04 ng/
mL and coefficient of variation (CV) <15%), insulin by the
Bayer ACS180 auto-analyser (CV 12%), and glucose by
the Bayer Alera chemistry analyser.
Statistical analysis
Results were analysed non-parametrically, using the
Mann–Whitney U, Kruskall-Wallis and Spearman cor-
relation tests. Multivariate analyses and power calcula-




In the PI group, 21 patients received LPV/r and one
Atazanavir for at least six months, with the median dur-
ation on PIs being 11.5 months. The median duration
on regimen 1 drugs prior to progression to regimen 2 was
15 months. Four (18%) patients received d4T and 13 (59%)
AZT, as part of their regimen. The median total duration
on these drugs were 15.5 and nine months, respectively.
In the non-PI group, 21 of the 22 patients received either
AZT or d4T, with median durations of 12 and 10 months,
respectively.
The median (interquartile range (IQR) ) age and BMI
among the groups were 36 (29; 42) years and 27 (24; 30),
respectively. Waist measurement and WHR did not differ
among the groups (Table 1).
Adiponectin levels in serum (Figure 1 and Table 1)
TA levels were within the reference interval (3.5 –
22 mg/L) [13] in all groups. However, total and HMW
adiponectin levels were significantly lower in both treat-
ment groups compared to the naïve group, with no sig-
nificant difference between the PI and non-PI groups. In
contrast, the HMW:TA ratio differed among all three
groups and was significantly lower in the PI group than
in both the non-PI and TN groups, and lower in the
non-PI group than in the TN group. This difference was
maintained when adjusting for BMI (data not shown)
(Table 1 and Figure 1).
Traditional markers of insulin resistance
There were no significant differences among the groups
for insulin, fasting and 2-h glucose, and the derived pa-
rameters HOMA-IR and QUICKI (Table 1). However, 15
(23%) of the entire study sample of HIV-infected pa-
tients had insulin resistance, defined as HOMA-IR >1.95
[14], and their HMW:TA ratios were lower (p = 0.0059)
(median 0.31, IQR 0.22 and 0.47) compared to those
without insulin resistance (median 0.50, IQR 0.40 and
0.57). Similarly, 40 (60%) of the entire sample of HIV-
infected patients were overweight (BMI ≥25) and had
Table 1 Adiponectin and markers of insulin resistance among the treatment groups (A), duration of therapy among
the groups (B)
(A) Adiponectin and markers of insulin resistance among the treatment groups
PI Median (IQR) Non-PI Median (IQR) TN Median (IQR) Units p-value
Age 34.5 (29.8; 41.0) 34.5 (31.3; 41.0) 35.5 (29.0; 41.0) Years 0.986
BMI 27.7 (24.9; 30.4) 25.0 (23.8; 29.5) 25.7 (22.9; 29.7) - 0.586
Waist 89 (82; 95) 83 (80; 93) 82 (76; 88) cm 0.194
WHR 0.87 (0.82; 0.93) 0.85 (0.79; 0.89) 0.84 (0.80; 0.90) - 0.315
Fasting insulin 5.5 (2.7; 10.1) 3.1 (2.1; 5.7) 4.4 (2.0; 8.0) mIU/L 0.365
Fasting glucose 86 (81; 90) 91 (83; 98) 91 (85; 97) mg/dL 0.145
2 hour glucose 104 (80; 113) 94 (85; 109) 94 (81; 109) mg/dL 0.877
HOMA-IR 1.18 (0.54; 2.09) 0.72 (0.50; 1.17) 1.05 (0.41; 1.73) - 0.479
QUICKI 0.37 (0.34; 0.42) 0.41 (0.37; 0.43) 0.38 (0.35; 0.45) - 0.234
Total adiponectin 5.6 (3.4; 9.4) 7.3 (4.0; 8.7) 9.0 (7.6; 12.1) ng/mL 0.039*
HMW adiponectin 2.2 (1.0; 3.9) 3.5 (1.8; 5.1) 5.3 (3.8; 7.0) ng/mL 0.002*
HMW:Total adiponectin 0.35 (0.29; 0.42) 0.48 (0.41; 0.56) 0.56 (0.52; 0.61) - <0.0001**
(B) Duration of therapy among the treatment groups
Regimen 1 15 (8.5; 21.5) 12 (9.5; 20.0) - Months
Regimen 2 11.5 (9.3; 14.0) - - Months
d4T 15.5 (9.8; 22.3) 10 (8; 17.5) - Months
AZT 9 (5; 16.5) 12 (11; 15.0) - Months
The Kruskall-Wallis and Mann–Whitney U tests were used to assess differences among the groups collectively and individually, respectively.
PI, protease inhibitor group; Non-PI, non-protease inhibitor group; TN, treatment-negative group; IQR, interquartile range; HMW, high molecular weight. *p < 0.05;
**p < 0.001. Multiply by the following conversion factor for SI units: glucose 0.0555 (mmol/L); insulin 6.945 (pmol/L).
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0.44, IQR 0.31 and 0.54) than those who were not over-
weight (median 0.50, IQR 0.44 and 0.58).
HMW, TA, and their ratio correlated negatively (p <0.05)
with waist, BMI, fasting insulin and HOMA-IR, even when
adjusted for BMI (Table 2). While HMW, TA, and their ra-
tio correlated positively (p < 0.05) with QUICKI, this signifi-
cance was lost when adjusting for BMI. When adjusting for
both BMI and total duration of therapy, only the HMW:TA
ratio maintained a significant correlation with fasted insu-
lin, HOMA-IR and QUICKI, while all three adiponectin
parameters remained significantly associated with waist.
TA, HMW and their ratio maintained their association
with waist, fasting insulin and HOMA-IR when adjusting
for duration of therapy alone. HMW and HMW:TA also
remained significantly associated with QUICKI when
adjusting for duration of therapy alone.Discussion
Altered body composition and insulin resistance are com-
ponents of the HIV–associated lipodystrophy syndrome
[7]. This syndrome is primarily seen in HIV-infected pa-
tients on HAART, with a 17% risk of developing lipody-
strophy after the first year of HAART and each additional
6 month period associated with a 45% risk [15]. These
findings are particularly associated with PIs, but similarfindings have been seen in some patients on nucleotide
and nucleoside analogues such as d4T, AZT and ddI [8].
Adiponectin has been implicated in the pathogenesis
of HIV– associated lipodystrophy [12], with PI adminis-
tration in mice producing a dose-related reduction in
adiponectin levels and administration of recombinant
adiponectin ameliorating the associated dyslipidaemia.
It was therefore somewhat surprising that TA levels
were well within the reference interval in all our study
groups. However, they were significantly lower in the HIV-
infected patients on HAART therapy (both PIs and non-
PIs) than in those not receiving treatment.
The active HMW form of adiponectin has been shown
to correlate better with insulin sensitivity than TA [16],
and has been shown to be low in HIV-infected patients
with insulin resistance [10]. In our study, HMW adipo-
nectin levels were significantly lower in patients receiv-
ing both PIs and non-PIs, but also in those receiving
only non-PIs. This finding in the latter group, may be at-
tributed to the use of d4T (16 (66%) patients) or AZT (5
(23%) patients), drugs which have both been associated
with lipodystrophy [17].
The HMW:TA ratio is a superior marker of insulin re-
sistance compared to total and HMW adiponectin levels
individually [18]. It is also an independent risk factor for
coronary vascular disease (CVD) [19]. Previous studies

















































































Figure 1 Distribution of (a) Total adiponectin, (b) HMW adiponectin, and (c) HMW: total adiponectin ratio among the three groups.
HMW, high molecular weight; PI, protease inhibitor group; Non-PI, non-protease inhibitor group; TN, treatment-negative group; KW,
Kruskall-Wallis; p <0.05 considered significant.
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Table 2 The relationship between adiponectin and various markers of insulin resistance before and after adjusting for BMI and duration of therapy, separately
and together
Relationship between adiponectin and markers of insulin resistance
Univariable Multivariable
Adjusted for BMI Adjusted for duration of therapy Adjusted for BMI and duration of therapy
b 95% CI p-value b 95% CI p-value b 95% CI p-value b 95% CI p-value
Total Adiponectin
Waist −0.27 (−0.3895,-0.1420) 0.0001** −0.28 (−0.5153,-0.0517) 0.019* −0.29 (−0.4582,-0.1161) 0.002* −0.35 (−0.6479,-0.0492) 0.028*
Fasted Insulin −0.28 (−0.4683,-0.0906) 0.005* −0.21 (−0.3945,-0.0164) 0.037* −0.28 (−0.5408,-0.0266) 0.036* −0.24 (−0.4935,0.0099) 0.067
HOMA-IR −1.11 (−1.8677,-0.3428) 0.006* −0.81 (−1.5741,-0.0551) 0.040* −1.21 (−2.3196,-0.1036) 0.038* −1.07 (−2.1435,0.0051) 0.058
QUICKI 14.20 (1.2607,27.1444) 0.035* 8.24 (−4.8207,21.3036) 0.221 15.25 (−0.2780,30.7806) 0.061 11.29 (−4.4271,26.9992) 0.167
HMW Adiponectin
Waist −0.17 (−0.2484,-0.0923) 0.0001** −0.19 (−0.3350,-0.0429) 0.014* −0.16 (−0.2637,-0.0627) 0.003* −0.19 (−0.3674,-0.0109) 0.044*
Fasted Insulin −0.17 (−0.2941,-0.0547) 0.006* −0.13 (−0.2475,-0.0078) 0.041* −0.17 (−0.3204,-0.0169) 0.035* −0.14 (−0.2918,0.0048) 0.065
HOMA-IR −0.69 (−1.1753,-0.2091) 0.007* −0.51 (−0.9903,-0.0273) 0.042* −0.72 (−1.3745,-0.0666) 0.037* −0.64 (−1.2681,-0.0022) 0.056
QUICKI 9.38 (1.2388,17.5231) 0.027* 5.67 (−2.5563,13.9009) 0.182 9.97 (0.9112,19.0352) 0.037* 7.66 (−1.5098,16.8289) 0.110
HMW: TA
Waist −0.007 (−0.0102,-0.0042) 0.000** −0.011 (−0.0165,-0.0054) 0.0003** −0.16 (−0.2637,-0.0627) 0.003* −0.007 (−0.0130,-0.0016) 0.016*
Fasted Insulin −0.008 (−0.0123,-0.0030) 0.002* −0.006 (−0.0109,-0.0014) 0.013* −0.007 (−0.0119,-0.0025) 0.005* −0.006 (−0.0111,-0.0018) 0.009*
HOMA-IR −0.03 (−0.0497,-0.0123) 0.002* −0.03 (−0.0442,-0.0063) 0.011* −0.03 (−0.0509,-0.0103) 0.005* −0.03 (−0.0479,-0.0084) 0.008*
QUICKI 0.42 (0.1036,0.7331) 0.011* 0.30 (−0.0230,0.6253) 0.073 0.44 (0.1586,0.7148) 0.004* 0.38 (0.0911,0.6598) 0.014*
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this ratio to be significantly lower in the PI and less so
(but nevertheless still significantly so) in the non-PI
groups. This may imply an increased risk for CVD in pa-
tients on HAART (consistent with the findings of others)
[20,21], with the risk for CVD increased when both PIs
and non-PIs are being used. This significantly lower
HMW:TA ratio in patients receiving both PIs and NRTIs
(with the majority, i.e. 17 of 22, of patients also receiv-
ing a thymidine analogue) confirms previous findings
that protease inhibitors and thymidine analogues induce
metabolic complications synergistically [7]. A limitation
in this study is that the PI group also contained the nu-
cleoside analogue ddI. Further studies are needed in the
absence of so called d-drugs to confirm the contribution
of PI drugs to the changes seen in this study.
Our patient groups were selected to exclude the pres-
ence of overt diabetes, and therefore it was not surpris-
ing that fasting glucose was not abnormal in any of the
groups. On the other hand, we were surprised by the
lack of difference in all measures of glucose tolerance and
insulin sensitivity among the groups (Table 1), despite the
difference seen among the groups in total and HMW adi-
ponectin. However, a larger study sample may be required
to verify this. The sample size was sufficiently powered
(75.5%) to detect a difference in HMW: TA, but not to
verify the lack of significant differences demonstrated for
the insulin resistance markers. A further limitation is that
visceral and subcutaneous adiposity were not quantita-
tively assessed. Notwithstanding, the relationship between
insulin resistance markers and adiponectin, previously
shown [5], was demonstrated here, with the HMW:TA
ratio shown to be significantly lower in patients (in all
groups) with established insulin resistance (HOMA-IR
greater than 1.95 [21]) and also significantly lower in pa-
tients with BMI greater than or equal to 25 than in those
with lower BMIs. Furthermore, adiponectin levels (high,
total and their ratio) correlated negatively with HOMA-IR
and positively with QUICKI. The HMW:TA ratio also
correlated negatively with waist, waist hip ratio (data not
shown), fasting insulin levels and BMI (data not shown) -
all markers of insulin resistance. While BMI and duration
of drug therapy collectively contribute to the association
seen between the markers of insulin resistance and the TA
and HMW adiponectin forms, they do not affect the asso-
ciations seen with the HMW:TA ratio.
Conclusion
These data demonstrate that both PI- and non-PI-
containing HAART regimens significantly lower the
HMW:TA ratio in HIV patients, with the ratio more
significantly decreased in the PI-containing regimen,
implying that PIs and NRTIs have an additive effect on the
HMW:TA ratio. Although the HMW:TA ratio correlatednegatively with indirect markers of insulin resistance, insu-
lin resistance was not demonstrated to be associated with
ARV drugs. We therefore propose that the HMW:TA ratio
may be an earlier or more sensitive marker of insulin re-
sistance in HIV-infected patients on HAART than conven-
tional markers or HMW and total adiponectin individually.
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